Repeated monthly epicutaneous challenges with diphenylcyclopropenone result in a clinically reproducible level of contact allergy in de novo sensitized individuals

K. F. Mose, F. Andersen, L Skov, Mads Almose Røpke, Thomas Litman, Peter S. Friedmann, K. E. Andersen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

Diphenylcyclopropenone (DPCP) has been used as an experimental contact allergen in humans and for topical immunotherapy of patients with alopecia areata. However, the efficacy is mostly based on case series. Randomized controlled clinical trials are lacking(1) , as is detailed descriptions of how repeated topical exposure to DPCP affect the level of hypersensitivity. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind176
Udgave nummer4
Sider (fra-til)1095–1097
ISSN0007-0963
DOI
StatusUdgivet - 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Repeated monthly epicutaneous challenges with diphenylcyclopropenone result in a clinically reproducible level of contact allergy in de novo sensitized individuals'. Sammen danner de et unikt fingeraftryk.

Citationsformater